Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), has announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).

Dr. Reddy's Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 5841.60 as compared to the previous close of Rs. 5866.40. The total number of shares traded during the day was 33440 in over 3697 trades.

The stock hit an intraday high of Rs. 5916.85 and intraday low of 5804.70. The net turnover during the day was Rs. 195795877.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY Saxagliptin MetforminHydrochloride ExtendedReleaseTablets US